ARTICLE | Company News
Medical Marketing cancer, infectious news
June 2, 2008 7:00 AM UTC
Medical Marketing plans to divest or out-license all programs outside its oncology programs for DNA vaccines and ruthenium chemotherapy. The company’s lead DNA cancer vaccine against prostate specific membrane antigen ( PSMA) using Genvax immunostimulant technology is in Phase I/II testing to treat prostate cancer. The company plans to begin a Phase I/II trial of ONCO 4417, its lead ruthenium chemotherapy, in 2009. Medical Marketing will discontinue development of ONCO 4403, a preclinical ruthenium chemotherapy, and will seek to in-license or acquire additional oncology platforms. ...